丹参川芎嗪注射液治疗早期高血压肾病的疗效以及对氧化应激的影响

探讨丹参川芎嗪注射液治疗早期高血压肾病的疗效以及对氧化应激的影响。方法方便选取该院自2015年1月—2015年6月收治的78例早期高血压肾病患者按照随机数字表法分为对照组和研究组,每组39例。对照组患者给予黄葵胶囊治疗,研究组患者在对照组治疗基础上加用丹参川芎嗪注射液治疗,14天为一个疗程,共进行两个疗程的治疗。比较两组患者治疗前后血清β2-微球蛋白(β2-MG)、血清胱抑素C(Cys-C)、血清超氧化物歧化酶(SOD)及丙二醛(MDA)水平差异。结果治疗前对照组与研究组血β2-MG和Cys-C水平分别为(3.89±0.45)、(5.43±0.36)mg/L和(3.92±0.63)、(5.52±0.43)mg/L,治疗后对照组与研究组血β2-MG和Cys-C水平分别为(1.99±0.32)、(1.55±0.26)mg/L和(1.16±0.46)、(0.89±0.37)mg/L,治疗后两组血β2-MG和Cys-C水平均较前明显降低(与同组治疗前相比,均P﹤0.05),且研究组降低更为明显(与对照组治疗后相比,均P﹤0.05)。治疗前对照组与研究组血SOD和MDA水平分别为(29.34±4.58)U/mL、(8.06±1.25)nmol/mL和(29.64±5.04)U/mL、(8.14±1.34)nmol/mL,治疗后对照组与研究组血SOD和MDA水平分别为(42.85±6.67)U/mL、(4.58±0.97)nmol/mL和(62.57±9.04)U/mL、(2.84±0.64)nmol/mL,治疗后两组血SOD水平较前均明显升高而MDA水平均明显降低(与同组治疗前相比,均P﹤0.05),且研究组变化更为明显(与对照组治疗后相比,均P﹤0.05),差异均有统计学意义。结论丹参川芎嗪注射液能够明显减轻早期高血压肾病患者体内的氧化应激程度,保护肾功能,提高治疗效果,值得在临床中推广应用。

Efficacy of Danshen ligustrazin Injection in the Treatment of Early Stage Hypertensive Nephropathy and its Effect on Oxidative Stress

Objective To investigate the efficacy of Danshen ligustrazin injection in the treatment of patients with early stage hypertension and its effect on oxidative stress. Methods 78 cases of early hypertensive nephropathy from January 2015 to June 2015admitted at our hospital were randomly divided into the control group and the research group, 39 cases in each group. The control group were treated with Huangkui capsule in the treatment,while the patients of research group were given Danshen ligustrazin injection based on the control group treatment.The courses were all 14 days and the treat-ment were two courses.To compare the levels of serum beta 2-microglobulin(β2-MG), serum cystatin C (Cys), serum super-oxide dismutase (SOD) and malondialdehyde (MDA) of before and after treatment of the two groups. Results The levels of serum β2-MG and Cys-C of the control and research group before treatment were respectively(3.89±0.45)mg/L,(5.43±0.36) mg/L and (3.92±0.63)mg/L,(5.52±0.43)mg/L;the levels of serum β2-MG and Cys-C of the control and research group after treatment were respectively (1.99±0.32)mg/L,(1.55±0.26)mg/L and(1.16±0.46)mg/L,(0.89±0.37)mg/L;the levels of β2-MG and Cys-C of all groups decreased obviously(compared with the pre-treatment,all P<0.05),and the research showed more ob-viously (compared with the control group,all P< 0.05).The levels of serum SOD and MDA of the control and research group before treatment were respectively (29.34±4.58)U/mL,(8.06±1.25)nmol/L and (29.64±5.04)U/mL,(8.14±1.34)nmol/L;the levels of serum SOD and MDA of the control and research group after treatment were respectively (42.85 ±6.67)U/mL, (4.58±0.97)nmol/L and (62.57±9.04)U/mL,(2.84±0.64)nmol/L;the levels of SOD and MDA of all groups decreased obvi-ously (compared with the pre-treatment,all P< 0.05),and the research showed more obviously (compared with the control group,all P< 0.05),the difference was statistically significant. Conclusion Danshen ligustrazin injection can significantly re-duce the degree of oxidative stress, protect renal function and improve the therapeutic effect in patients with early stage of hypertension, and it is worth to be popularized in clinical practice.